Biological Activity of FGF-23 Fragments

Overview

Journal Pflugers Arch

Specialty Physiology

Date 2007 Mar 3

PMID 17333246

Citations 32

Authors

Theresa J Berndt

Theodore A Craig

Daniel J McCormick

Beate Lanske

Despina Sitara

Mohammed S Razzaque

Marlon Pragnell

Ann E Bowe

Stephen P OBrien

Susan C Schiavi

Rajiv Kumar

Affiliations

Soon will be listed here.

Abstract

The phosphaturic activity of intact, full-length, fibroblast growth factor-23 (FGF-23) is well documented. FGF-23 circulates as the intact protein and as fragments generated as the result of proteolysis of the full-length protein. To assess whether short fragments of FGF-23 are phosphaturic, we compared the effect of acute, equimolar infusions of full-length FGF-23 and various FGF-23 fragments carboxyl-terminal to amino acid 176. In rats, intravenous infusions of full-length FGF-23 and FGF-23 176-251 significantly and equivalently increased fractional phosphate excretion (FE Pi) from 14 +/- 3 to 32 +/- 5% and 15 +/- 2 to 33 +/- 2% (p < 0.001), respectively. Chronic administration of FGF-23 176-251 reduced serum Pi and serum concentrations of 1alpha,25-dihydroxyvitamin D. Shorter forms of FGF-23 (FGF-23 180-251 and FGF-23 184-251) retained phosphaturic activity. Further shortening of the FGF-23 carboxyl-terminal domain, however, abolished phosphaturic activity, as infusion of FGF-23 206-251 did not increase urinary phosphate excretion. Infusion of a short fragment of the FGF-23 molecule, FGF-23 180-205, significantly increased FE Pi in rats and reduced serum Pi in hyperphosphatemic Fgf-23 ( -/- ) knockout mice. The activity of FGF-23 180-251 was confirmed in opossum kidney cells in which the peptide reduced Na(+)-dependent Pi uptake and enhanced internalization of the Na(+)-Pi IIa co-transporter. We conclude that carboxyl terminal fragments of FGF-23 are phosphaturic and that a short, 26-amino acid fragment of FGF-23 retains significant phosphaturic activity.

Citing Articles

Exploring endocrine FGFs - structures, functions and biomedical applications.

Phan P, Ternier G, Edirisinghe O, Kumar T Int J Biochem Mol Biol. 2024; 15(4):68-99.

PMID: 39309613 PMC: 11411148. DOI: 10.62347/PALK2137.

Vitamin D Supplementation for 12 Months in Older Adults Alters Regulators of Bone Metabolism but Does Not Change Wnt Signaling Pathway Markers.

Christodoulou M, Aspray T, Piec I, Washbourne C, Tang J, Fraser W JBMR Plus. 2022; 6(5):e10619.

PMID: 35509637 PMC: 9059470. DOI: 10.1002/jbm4.10619.

The Saga of Endocrine FGFs.

Phan P, Saikia B, Sonnaila S, Agrawal S, Alraawi Z, Kumar T Cells. 2021; 10(9).

PMID: 34572066 PMC: 8465397. DOI: 10.3390/cells10092418.

Antenatal iron supplementation, FGF23, and bone metabolism in Kenyan women and their offspring: secondary analysis of a randomized controlled trial.

Braithwaite V, Mwangi M, Jones K, Demir A, Prentice A, Prentice A Am J Clin Nutr. 2021; 113(5):1104-1114.

PMID: 33675347 PMC: 8106766. DOI: 10.1093/ajcn/nqaa417.

Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia.

Whyte M, Zhang F, Wenkert D, Mumm S, Berndt T, Kumar R Bone. 2020; 134:115300.

PMID: 32112990 PMC: 7233305. DOI: 10.1016/j.bone.2020.115300.

References

Sitara D, Razzaque M, Hesse M, Yoganathan S, Taguchi T, Erben R . Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23(7):421-32. PMC: 2894977. DOI: 10.1016/j.matbio.2004.09.007. View

Sitara D, Razzaque M, St-Arnaud R, Huang W, Taguchi T, Erben R . Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol. 2006; 169(6):2161-70. PMC: 1762489. DOI: 10.2353/ajpath.2006.060329. View

Yamashita T, Yoshioka M, Itoh N . Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000; 277(2):494-8. DOI: 10.1006/bbrc.2000.3696. View

. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-8. DOI: 10.1038/81664. View

White K, Jonsson K, Carn G, Hampson G, Spector T, Mannstadt M . The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001; 86(2):497-500. DOI: 10.1210/jcem.86.2.7408. View

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S . Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98(11):6500-5. PMC: 33497. DOI: 10.1073/pnas.101545198. View

Bowe A, Finnegan R, Jan de Beur S, Cho J, Levine M, Kumar R . FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. 2001; 284(4):977-81. DOI: 10.1006/bbrc.2001.5084. View

Cancilla B, Davies A, Cauchi J, Risbridger G, Bertram J . Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int. 2001; 60(1):147-55. DOI: 10.1046/j.1523-1755.2001.00781.x. View

White K, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom T, Econs M . Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001; 60(6):2079-86. DOI: 10.1046/j.1523-1755.2001.00064.x. View

10.

Fukumoto S, Yamashita T . Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens. 2002; 11(4):385-9. DOI: 10.1097/00041552-200207000-00003. View

11.

Schiavi S, Moe O . Phosphatonins: a new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens. 2002; 11(4):423-30. DOI: 10.1097/00041552-200207000-00009. View

12.

Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K . Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002; 143(8):3179-82. DOI: 10.1210/endo.143.8.8795. View

13.

Yamashita T, Konishi M, Miyake A, Inui K, Itoh N . Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem. 2002; 277(31):28265-70. DOI: 10.1074/jbc.M202527200. View

14.

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T . Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11):4957-60. DOI: 10.1210/jc.2002-021105. View

15.

Benet-Pages A, Orlik P, Strom T, Lorenz-Depiereux B . An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2004; 14(3):385-90. DOI: 10.1093/hmg/ddi034. View

16.

Yan X, Yokote H, Jing X, Yao L, Sawada T, Zhang Y . Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells. 2005; 10(5):489-502. DOI: 10.1111/j.1365-2443.2005.00853.x. View

17.

Bai X, Miao D, Goltzman D, Karaplis A . The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003; 278(11):9843-9. DOI: 10.1074/jbc.M210490200. View

18.

Campos M, Couture C, Hirata I, Juliano M, Loisel T, Crine P . Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J. 2003; 373(Pt 1):271-9. PMC: 1223479. DOI: 10.1042/BJ20030287. View

19.

Riminucci M, Collins M, Fedarko N, Cherman N, Corsi A, White K . FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003; 112(5):683-92. PMC: 182207. DOI: 10.1172/JCI18399. View

20.

Steiling H, Werner S . Fibroblast growth factors: key players in epithelial morphogenesis, repair and cytoprotection. Curr Opin Biotechnol. 2003; 14(5):533-7. DOI: 10.1016/j.copbio.2003.08.003. View